Involvement of protein aggregation in Parkinson’s disease and Alzheimer’s disease has long been documented but the mechanisms causing pathology is remain still unknown. In the proposed study, aggregate stages of alpha-synuclein and tau will be investigated using proteomics to identify interacting proteins involved in their clearance. Importantly, a great part of the project will be centered on validations in models to address therapeutic potential of the identified regulators

Tribe Takeaway er det eneste takeaway software system som gør, at restauranter kan tage bestilling og betaling af takeaway direkte på Facebook og Instagram. Tribe Takeaway vil disrupte takeaway markedet med et bæredygtigt socialt takeaway system. Et system til både restaurantens egne salgskanaler, sociale medier og en portal/app. Tribe Takeaway's image er gennemsyret af vores bæredygtige koncept. For hvert måltid som bestilles via softwaren, deles samtidigt et måltid til et barn i hungersnød.

Heterogeneity in breast cancer (BC) poses a significant challenge to cancer detection and medicine and an array of subtype sensitive biomarkers could boost the diagnosis. We will here deliver an integrative bioinformatic automatized pipeline to analyse at multiple biological levels different for accurate molecular profiling of BC diversity exploiting the recently discovered 'liquid biopsies' as a source of biomakers that will be ultimately delivered in the blood stream.

Full chemical understanding of the shea kernel will facilitate growth and value creation on one of the last rural crops: The West African (WA) shea kernel. Better understanding of the shea kernel process, from collection to final product, will secure a controlled and sustainable industrialized operation.This will reduce the loss in the supply chain from 30% to <10%, ensure an increase in the volume of shea kernels by up to 100% and opening for future production in Denmark of high-value ingredients for food and cosmetic industry. Sheaine is a strong interdisciplinary public-private partnership between AAK DK, global leaders in shea processing and University of Copenhagen.

In this research programme we will develop and validate state-of-the-art Artificial Intelligence based models for Breast Cancer (BC) routine histopathology classification and for improved patient stratification in respect to prognosis and treatment response. Through both retrospective and prospective validation of the developed models, we will establish evidence towards future clinical translation. Our studies are based on large-scale population samples (>35,000 whole slide images), ensuring unbiased data and models. Novel methodologies for stain-free and multi-stain analysis will also be developed, which has the potential to contribute to improved models and advancing the field of digital pathology. The project aims to improve the quality of BC histopathology assessments by reducing errors and inter-assessor variability, enhancing patient stratification and reducing over- and under-treatment of patients, while also contributing toward more efficient/reliable routine pathology.

Bactolife udvikler et alternativ til antibiotika i mennesker og i dyrefoder. Det første produkt, Ablactomab, testes som led i dette Innobooster projekt in vitro og in vivo til behandling af fravænningsdiarré i smågrise. Ablactomab vil være det eneste alternativ til brug af antibiotika, zinc og kobber i denne type infektion.

Ud fra erfaringerne fra det maritime marked ønsker vi at udvikle rundstråleantenner til det landbaserede område, hvor kravene til frekvenser og sendestyrker adskiller sig fra det maritime område. Vi har derfor behov for at udvikle nye antennetyper for at kunne gå ind på dette marked.

Evaxion develops vaccines against bacterial pathogens by discovering protective proteins using an in-house AI platform called EDEN. These proteins are cumbersome to design and develop for clinical testing, with significant preclinical development costs. We aim to greatly accelerate this process by generating improved structural models of the identified proteins using novel methodologies within deep learning and probabilistic programming, thus allowing the generation of clinically ready designs.

Lugtgener fra bilens ventilationsanlæg pga. akkumulering af bakterier og svamp er et velkendt problem, som kan have konsekvenser for sundhed og indeklima. ACD ApS har udviklet en innovativ løsning, ACD-Plugin, som er et lille UVC LED-lys i form af et plugin, tilpasset snævre og sværttilgængelige ventilationssystemer, som det der findes i biler. Den desinficerende effekt af UVC forstærkes af en antibakteriel TiO2-behandling, som med påvist effekt udraderer akkumulerede patogene.

ACOUPLAST aims to reach a 900M€/year market opportunity with the development of a polymer acoustofluidic chip for high-performing, fast and cost-effective plasma separation, to enable healthcare and veterinary Point-of-Care (PoC) diagnostics. Targeting life science companies, we will deliver AcouPlast chip modules for integration in single-use test cartridges. The solution is a recent research breakthrough by DTU Physics, experimentally validated by ACS, resulting in a patent application.

Akromegali er en sjælden sygdom forårsaget af øget niveauer af væksthormon, hvilket ofte er forårsaget af en godartet tumor i hypofysen. Flere studier peger på, at GIP receptoren (GIPR) kan forårsage de øgede væksthormonniveauer i en del af patienterne med akromegali. Vi er i den unikke situation, at vi har en GIPR antagonist, som kan bruges i mennesker. Med den vil vi klarlægge GIPRs involvering i akromegali og validere om GIPR antagonister kan bruges terapeutisk i denne patientgruppe.

Chronic pain affects more than 1.5 billion individuals globally – and is the single most prevalent symptom among geriatric patients. Chronic pain has tremendous impact on individuals’ wellbeing, lifestyle, independence, activity and comfort, and the condition is associated with the spiral degeneration of general quality of life of older adults, with increased disability, deconditioning and hence, increased change on frailty. ActiVITAE aims to help people ageing well by alleviating geriatric chronic pain using our completely novel and patented, ICT-based pain management system. The solution, Vibration Induced Treatment by Abdominal Excitation (VITAE), is disruptive and provides a pleasant, non-invasive Vagal Nerve Stimulation (VNS), utilising abdominal vibro-tactile stimulation of the Pacinian corpuscles.

The project goal is to bring to the clinical market and mass market an easily accessible, user-friendly and motivating digital medical device called (Alzheimer’s disease) AD Shield, delivered on tablets, smartphones and PCs/Mac. The main result will offer presymptomatic detection of AD and personalized AD prevention programs in the form of gamified cognitive training and behavioural interventions in one seamless product. The product targets citizens with the highest risk of AD (due to an acute unmet clinical need) and the healthcare professionals that serve these segments. OVERALL AMBITION: The goal is to create and become the global standard for presymptomatic AD care.